An important role of MAPK pathway activation as a therapeutic target in MPN has been confirmed by the efficacy of combined JAK2 and MEK inhibition in preclinical models and patient cells observed with clinical and preclinical compounds including binimetinib, selumetinib, trametinib, and PD0325901 [18, 19]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.